<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://www.onhealthcare.tech/p/how-fda-predetermined-change-control</loc><news:news><news:publication><news:name>Thoughts on Healthcare Markets &amp; Technology</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-10-29T00:04:23+00:00</news:publication_date><news:title>How FDA predetermined change control plans create a market for AI medical device validation, clinical data procurement, software release controls, and recurring regulatory evidence services</news:title></news:news></url><url><loc>https://www.onhealthcare.tech/p/part-ii-how-fda-predetermined-change</loc><news:news><news:publication><news:name>Thoughts on Healthcare Markets &amp; Technology</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-10-28T23:47:51+00:00</news:publication_date><news:title>Part II: How FDA predetermined change control plans create a market for AI medical device validation, clinical data procurement, software release controls, and recurring regulatory evidence services</news:title></news:news></url><url><loc>https://www.onhealthcare.tech/p/part-i-how-fda-predetermined-change</loc><news:news><news:publication><news:name>Thoughts on Healthcare Markets &amp; Technology</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-10-28T23:46:38+00:00</news:publication_date><news:title>Part I: How FDA predetermined change control plans create a market for AI medical device validation, clinical data procurement, software release controls, and recurring regulatory evidence services</news:title></news:news></url></urlset>